130 related articles for article (PubMed ID: 3296302)
21. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
Fitscha P; Kaliman J; Sinzinger H
Am J Hematol; 1985 May; 19(1):13-9. PubMed ID: 3885723
[TBL] [Abstract][Full Text] [Related]
22. Interaction of receptors for prostaglandin E1/prostacyclin and insulin in human erythrocytes and platelets.
Dutta-Roy AK; Kahn NN; Sinha AK
Life Sci; 1991; 49(16):1129-39. PubMed ID: 1654491
[TBL] [Abstract][Full Text] [Related]
23. Purification and properties of prostaglandin E1/prostacyclin receptor of human blood platelets.
Dutta-Roy AK; Sinha AK
J Biol Chem; 1987 Sep; 262(26):12685-91. PubMed ID: 2887571
[TBL] [Abstract][Full Text] [Related]
24. 6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.
Quilley CP; McGiff JC; Lee WH; Sun FF; Wong PY
Hypertension; 1980; 2(4):524-8. PubMed ID: 6995292
[TBL] [Abstract][Full Text] [Related]
25. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets.
Ashby B
Mol Pharmacol; 1990 Jul; 38(1):46-53. PubMed ID: 1695318
[TBL] [Abstract][Full Text] [Related]
26. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
Jaschonek K; Renn W; Weisenberger H
Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
[No Abstract] [Full Text] [Related]
27. (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets.
Corsini A; Folco GC; Fumagalli R; Nicosia S; Noe MA; Oliva D
Br J Pharmacol; 1987 Jan; 90(1):255-61. PubMed ID: 3545351
[TBL] [Abstract][Full Text] [Related]
28. Identification of the prostacyclin receptor by use of [15-3H1]19-(3-azidophenyl)-20-norisocarbacyclin, an irreversible specific photoaffinity probe.
Ito S; Hashimoto H; Negishi M; Suzuki M; Koyano H; Noyori R; Ichikawa A
J Biol Chem; 1992 Oct; 267(28):20326-30. PubMed ID: 1400351
[TBL] [Abstract][Full Text] [Related]
29. Heparin-mediated neutralization of platelet antiaggregatory activity of prostacyclin (PGI2): studies on mechanism.
Saba SR; Saba HI
Am J Hematol; 1985 Oct; 20(2):97-105. PubMed ID: 3898823
[TBL] [Abstract][Full Text] [Related]
30. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
Wong PY; Lee WH; Chao PH; Reiss RF; McGiff JC
J Biol Chem; 1980 Oct; 255(19):9021-4. PubMed ID: 6997309
[TBL] [Abstract][Full Text] [Related]
31. Platelet-stimulated thrombin and PDGF are normalized by insulin and Ca2+ channel blockers.
Kahn NN
Am J Physiol; 1999 May; 276(5):E856-62. PubMed ID: 10329979
[TBL] [Abstract][Full Text] [Related]
32. Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor.
Thierauch KH; Stürzebecher CS; Schillinger E; Rehwinkel H; Radüchel B; Skuballa W; Vorbrüggen H
Prostaglandins; 1988 Jun; 35(6):855-68. PubMed ID: 2847246
[TBL] [Abstract][Full Text] [Related]
33. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
Wong PY; McGiff JC; Sun FF; Lee WH
Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
[TBL] [Abstract][Full Text] [Related]
34. Human prostacyclin platelet receptors in diabetes mellitus.
Modesti PA; Fortini A; Gensini GF; Vanni D; Prisco D; Abbate R
Thromb Res; 1991 Sep; 63(5):541-8. PubMed ID: 1755006
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets.
Jakubowski JA; Utterback BG; Mais DE; Hardinger SA; Braish TF; Nevill CR; Fuchs PL
Prostaglandins; 1994 Mar; 47(3):189-201. PubMed ID: 8016389
[TBL] [Abstract][Full Text] [Related]
36. Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man.
Modesti PA; Fortini A; Poggesi L; Boddi M; Abbate R; Gensini GF
Thromb Res; 1987 Dec; 48(6):663-9. PubMed ID: 2448896
[TBL] [Abstract][Full Text] [Related]
37. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J
Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639
[TBL] [Abstract][Full Text] [Related]
38. [3H]iloprost and prostaglandin E2 compete for the same receptor site on cardiac sarcolemmal membranes.
Lerner RW; Lopaschuk GD; Catena RC; Olley PM
Biochim Biophys Acta; 1992 Apr; 1105(2):189-92. PubMed ID: 1375098
[TBL] [Abstract][Full Text] [Related]
39. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
40. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Schrör K; Löbel P; Steinhagen-Thiessen E
Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
